Institute of Human Genetics, Diagnostic and Research Center for Molecular BioMedicine, Medical University of Graz, Graz, Austria; BioTechMed-Graz, Graz, Austria; Christian Doppler Laboratory for Liquid Biopsies for Early Detection of Cancer, Graz, Austria.
Institute of Human Genetics, Diagnostic and Research Center for Molecular BioMedicine, Medical University of Graz, Graz, Austria.
Trends Mol Med. 2020 May;26(5):519-528. doi: 10.1016/j.molmed.2020.01.012. Epub 2020 Feb 17.
Cell-free DNA (cfDNA) is evolving into a widely used prognostic and predictive biomarker, particularly in oncology. However, its versatile clinical use precedes a profound understanding of the underlying biology of cfDNA release. There is much evidence to suggest that cfDNA is mainly derived from dying (i.e., apoptotic) cells. However, numerous cancer studies have shown that cfDNA is informative about acquired resistance to given therapies, which is present in living, proliferating tumor subclones. To explain this contradiction, we review current insights regarding cfDNA release, in particular the interplay between apoptosis and proliferation. We describe how improved knowledge about cfDNA biology could be used for novel therapeutic strategies and how this may affect patient management.
无细胞游离 DNA（cfDNA）正在发展成为一种广泛应用的预后和预测生物标志物，尤其是在肿瘤学领域。然而，在深入了解 cfDNA 释放的基础生物学之前，其广泛的临床应用已经出现。有大量证据表明，cfDNA 主要来源于死亡（即凋亡）细胞。然而，许多癌症研究表明，cfDNA 可以提供有关对特定治疗产生获得性耐药的信息，而这些信息存在于活的、增殖的肿瘤亚克隆中。为了解释这一矛盾，我们回顾了目前关于 cfDNA 释放的见解，特别是凋亡和增殖之间的相互作用。我们描述了如何利用对 cfDNA 生物学的深入了解来制定新的治疗策略，以及这将如何影响患者管理。
